6,602 results match your criteria Retinal Vein Occlusion


Intraoperative three-dimensional fluorescein angiography-guided pars plana vitrectomy for branch retinal vein occlusion.

Retin Cases Brief Rep 2020 Nov 25. Epub 2020 Nov 25.

1Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine. 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Purpose: To show surgical results of the intraoperative three-dimensional fluorescein angiography (3D-FA)-guided pars plana vitrectomy (PPV) for branch retinal vein occlusion (BRVO) with vitreous hemorrhage (VH) and neovascularization elsewhere (NVE).

Methods: The NGENUITY 3D ® visualization system was used for the digital assisted vitrectomy (DAV). 3D-FA-guided PPV was performed in three patients with BRVO with VH and NVE. Read More

View Article and Full-Text PDF
November 2020

A Review of Aflibercept Treatment for Macular Disease.

Ophthalmol Ther 2021 Jun 13. Epub 2021 Jun 13.

National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.

Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. Read More

View Article and Full-Text PDF

Long-term outcomes of anti-VEGF treatment of retinal vein occlusion.

Eye (Lond) 2021 Jun 11. Epub 2021 Jun 11.

Sydney Retina Clinic, Sydney, NSW, Australia.

Background/objectives: To analyze the long-term outcomes of eyes with retinal vein occlusion (RVO) 8 years after commencing treatment with anti-vascular endothelial growth factor (VEGF) agents.

Subjects/methods: Retrospective, multicentre study of 221 eyes diagnosed with RVO, which were commenced on anti-VEGF therapy between 2009 and 2011. VA and CRT were recorded at baseline and at subsequent annual time points. Read More

View Article and Full-Text PDF

Vitreoretinal Complications in Boston Keratoprosthesis Type 1.

Am J Ophthalmol 2021 Jun 6. Epub 2021 Jun 6.

Department of Ophthalmology, Université de Montréal, Montréal, Québec, Canada. Electronic address:

Purpose: To evaluate the incidence of vitreoretinal complications, treatment modalities, and the visual outcomes in a large cohort of eyes that underwent Boston Keratoprosthesis (KPro) implantation.

Design: Retrospective, interventional case series.

Methods: 132 eyes of 114 patients who underwent KPro implantation at the Centre Hospitalier de l'Université de Montréal from 2008 to 2017 were included with at least 1 year follow-up. Read More

View Article and Full-Text PDF

Real-World Outcomes in Patients with Branch Retinal Vein Occlusion- (BRVO-) Related Macular Edema Treated with Anti-VEGF Injections Alone versus Anti-VEGF Injections Combined with Focal Laser.

J Ophthalmol 2021 19;2021:6641008. Epub 2021 May 19.

Retina Consultants of Alabama, The University of Alabama, Birmingham Department of Ophthalmology, Birmingham, AL 35233, USA.

The purpose of this study was to assess outcomes in a real-world nonclinical trial setting of antivascular endothelial growth factor (VEGF) injections alone vs. focal laser combined with anti-VEGF injections in patients with branch retinal vein occlusion- (BRVO-) related macular edema (ME). This study included 88 BRVO with ME patients who were treated over three years at both a tertiary referral center in the Birmingham metropolitan area and satellites in rural Alabama. Read More

View Article and Full-Text PDF

Anatomic-Functional Correlates in Lesions of Retinal Vein Occlusion.

Invest Ophthalmol Vis Sci 2021 Jun;62(7):10

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, United Kingdom.

Purpose: To evaluate anatomic-functional associations at sites of retinal lesions in retinal vein occlusion (RVO).

Methods: This pilot, prospective, observational study was conducted at the Northern Ireland Clinical Research Facility (NICRF) of Queen's University and the Belfast Health and Social Care Trust, Northern Ireland, between August 1, 2018, and September 30, 2019. The study included 10 treatment-naïve patients with RVO (10 RVO eyes and 10 fellow eyes). Read More

View Article and Full-Text PDF

Clinical significance of subclinical atherosclerosis in retinal vein occlusion.

Sci Rep 2021 Jun 7;11(1):11905. Epub 2021 Jun 7.

Division of Cardiology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153 Gyeongchun-ro, Guri, Gyeonggi-do, 11923, Republic of Korea.

Retinal vein occlusion (RVO) is associated with atherosclerotic cardiovascular risk factors; however, its association with the specific markers of subclinical atherosclerosis has not yet been established. To investigate this association, we compared 70 patients with RVO to 70 age- and sex-matched patients without RVO. Low-density lipoprotein cholesterol (LDL-C) levels and brachial-ankle pulse wave velocity (baPWV) were significantly higher in the RVO group than in the control group. Read More

View Article and Full-Text PDF

Concurrent branch retinal artery occlusion in central retinal vein occlusion: 3 cases reports and literature review.

Authors:
Neha Goel

Saudi J Ophthalmol 2020 Jul-Sep;34(3):212-215. Epub 2021 Feb 27.

Department of Vitreoretina, ICARE Eye Hospital and Postgraduate Institute, NOIDA, Uttar Pradesh, India.

Concurrent branch retinal artery occlusion (BRAO) and central retinal vein occlusion (CRVO) are the infrequently encountered clinical entities, with only a handful of cases elaborated in the literature. This case series describes three patients who presented with a dramatic fundus appearance that led to the diagnosis of unilateral BRAO and CRVO. Hypertension could be identified as a predisposing factor in only one patient. Read More

View Article and Full-Text PDF
February 2021

Full-thickness macular hole formation following antivascular endothelial growth factor injection in a case of hemicentral retinal vein occlusion.

Oman J Ophthalmol 2021 Jan-Apr;14(1):49-51. Epub 2021 Feb 27.

Department of Retina and Uvea Services, Priyamvada Birla Aravind Eye Hospital, Kolkata, West Bengal, India.

A rare case reporting the occurrence of full-thickness macular hole (MH) formation following intravitreal antivascular endothelial growth factor injection in a case of hemicentral retinal vein occlusion and the subsequent management of the case. As described in few other similar case reports in the literature, there are quite a few probabilities of factors causing this pathology. An acute posterior vitreous detachment or sudden decompression of the macular edema can quite possibly lead to the above situation. Read More

View Article and Full-Text PDF
February 2021

Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment.

Ther Clin Risk Manag 2021 26;17:489-496. Epub 2021 May 26.

Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Background: To evaluate the anatomic and functional outcomes in eyes of patients with macular edema (ME) caused by central retinal vein occlusion (CRVO) who were lost to follow-up (LTFU) for more than 6 months following treatment with anti-vascular endothelial growth factor (VEGF) therapy and to determine the predictive factors of visual prognosis in these patients.

Methods: This study was conducted as a retrospective, case series investigation. Patients whose eyes were receiving intravitreal anti-VEGF treatment for CRVO-ME, with the next follow-up visit occurring more than 6 months following treatment were identified. Read More

View Article and Full-Text PDF

Impact of kidney transplantation on the risk of retinal vein occlusion in end-stage renal disease.

Sci Rep 2021 Jun 2;11(1):11583. Epub 2021 Jun 2.

Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

It has been known that retinal vein occlusion (RVO) is associated with chronic kidney disease, especially end-stage renal disease (ESRD). However, little is known about the effect of kidney transplantation (KT) on RVO incidence in ESRD patients. This study aimed to compare the incidence of RVO in KT recipients (n = 10,498), matched ESRD patients (n = 10,498), and healthy controls (HCs, n = 10,498), using a long-term population-based cohort. Read More

View Article and Full-Text PDF

Significant elevation of aqueous endothelin-1 in central retinal vein occlusion.

PLoS One 2021 2;16(6):e0252530. Epub 2021 Jun 2.

Department of Ophthalmology, Konyang University Hospital, Daejeon, Republic of Korea.

Purpose: To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group.

Methods: A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month. Read More

View Article and Full-Text PDF

Assessment of Patients' Confidence Regarding a New Triage Concept in a Medical Retina Clinic during the First COVID-19 Outbreak.

Int J Environ Res Public Health 2021 May 29;18(11). Epub 2021 May 29.

Department of Ophthalmology, University Hospital of Zurich, 8091 Zurich, Switzerland.

Background: During the first COVID-19 pandemic outbreak, a new triage concept had to be implemented for patients with retinal diseases having a scheduled appointment at the medical retina clinic. In this study, we aimed to assess patients' confidence in this triage concept and patients' satisfaction regarding the received treatment during the outbreak.

Methods: This retrospective study included all patients with a diagnosed retinal disease, triaged into three priority groups based on their condition's urgency during lockdown. Read More

View Article and Full-Text PDF

Red Blood Cells: Tethering, Vesiculation, and Disease in Micro-Vascular Flow.

Diagnostics (Basel) 2021 May 27;11(6). Epub 2021 May 27.

Department of Bioengineering, University of California, San Diego, CA 92093-0412, USA.

The red blood cell has become implicated in the progression of a range of diseases; mechanisms by which red cells are involved appear to include the transport of inflammatory species via red cell-derived vesicles. We review this role of RBCs in diseases such as diabetes mellitus, sickle cell anemia, polycythemia vera, central retinal vein occlusion, Gaucher disease, atherosclerosis, and myeloproliferative neoplasms. We propose a possibly unifying, and novel, paradigm for the inducement of RBC vesiculation during vascular flow of red cells adhered to the vascular endothelium as well as to the red pulp of the spleen. Read More

View Article and Full-Text PDF

Bilateral Retinal Vein Occlusion-Simulated Coats' Disease.

Diagnostics (Basel) 2021 May 19;11(5). Epub 2021 May 19.

Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China.

Retinal vein occlusion (RVO) is a differential diagnosis for Coats' disease due to retinal arterial Leber's aneurysms. Occasionally, RVO shows a Coats-like appearance. The differential diagnosis between Coats' disease and RVO is essential for clinical therapy, especially for those obsolete RVOs with collateral vessels and without retinal hemorrhage. Read More

View Article and Full-Text PDF

Oxidative Stress and Inflammation in Retinal Degeneration.

Antioxidants (Basel) 2021 May 17;10(5). Epub 2021 May 17.

Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

Inflammation and oxidative stress play prominent roles in the pathogenesis of many degenerative diseases of the retina, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion, and retinitis pigmentosa [... Read More

View Article and Full-Text PDF

The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion.

Graefes Arch Clin Exp Ophthalmol 2021 Jun 1. Epub 2021 Jun 1.

Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan District, Changchun, Jilin, 130041, China.

Purpose: To determine the correlation between aqueous humor cytokine levels and the prognostic value of anti-vascular endothelial growth factor (VEGF) therapy for treating macular edema resulting from retinal vein occlusion (RVO-ME).

Methods: This prospective study included 47 RVO-ME and 32 senile cataract cases. Aqueous humor collection was performed in patients with RVO-ME before intravitreal injection of ranibizumab and in patients before cataract surgery. Read More

View Article and Full-Text PDF

A Multimodal Imaging-Based Deep Learning Model for Detecting Treatment-Requiring Retinal Vascular Diseases: Model Development and Validation Study.

JMIR Med Inform 2021 May 31;9(5):e28868. Epub 2021 May 31.

College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Background: Retinal vascular diseases, including diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), myopic choroidal neovascularization (mCNV), and branch and central retinal vein occlusion (BRVO/CRVO), are considered vision-threatening eye diseases. However, accurate diagnosis depends on multimodal imaging and the expertise of retinal ophthalmologists.

Objective: The aim of this study was to develop a deep learning model to detect treatment-requiring retinal vascular diseases using multimodal imaging. Read More

View Article and Full-Text PDF

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review.

J Ophthalmol 2021 17;2021:6678364. Epub 2021 May 17.

Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.

Corticosteroids are used in a variety of ophthalmological diseases. One challenge faced by ophthalmologists is to deliver corticosteroids to the posterior segment of the eye with efficacy and safety. Sustained-release corticosteroid implants may be the answer to this problem. Read More

View Article and Full-Text PDF

Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year.

J Ophthalmol 2021 17;2021:6645452. Epub 2021 May 17.

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Purpose: To observe the changes in macular microvascular structure and the correlation between anatomy and visual function in patients with macular edema secondary to branch retinal vein occlusion (BRVO) treated with antivascular endothelial growth factor for one year.

Methods: This prospective study enrolled 39 patients (one eye per patient) who received intravitreal injections of ranibizumab for macular edema secondary to BRVO. All patients received a minimum of 3 initial monthly ranibizumab injections and criteria-driven pro re nata (PRN) dosing thereafter for visual acuity (VA) and central retinal thickness (CRT) stabilization. Read More

View Article and Full-Text PDF

Photopigment Bleaching Phenomenon on Fluorescein Angiography in a Patient with Impending Central Retinal Vein Occlusion.

J Ophthalmic Vis Res 2021 Apr-Jun;16(2):291-294. Epub 2021 Apr 29.

Retina & Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Purpose: To present the second case of photopigment bleaching phenomenon in fluorescein angiography (FA) and the first case of this phenomenon due to impending central retinal vein occlusion (CRVO).

Case Report: A 32-year-old healthy female noticed blurred vision in her right eye one day before presentation. Despite the 20/20 visual acuity at presentation, mild increased retinal vascular tortuosity and unilateral photopigment bleaching phenomenon in FA was observed in the right eye. Read More

View Article and Full-Text PDF

An Unusual Case of Concurrent Central Retinal Vein and Cilioretinal Artery Occlusion in a Healthy Patient.

Case Rep Ophthalmol 2021 May-Aug;12(2):407-411. Epub 2021 May 10.

Mount Elizabeth Novena Hospital, Singapore, Singapore.

It is rare for young, healthy patients to have retinal venous or arterial occlusions and even rarer for both to occur in concert. Such an occurrence should prompt a rapid and extensive workup to prevent further complications. We present our patient, a 37-year-old Lebanese male, who reported a 3-day history of blurring of vision in his left eye. Read More

View Article and Full-Text PDF

Retinal Vein Occlusion and Risk of Dementia: A Nationwide Population-Based Cohort Study.

Am J Ophthalmol 2021 May 26. Epub 2021 May 26.

Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article and Full-Text PDF

Comment on: Retinal vein occlusion and the risk of dementia: A nationwide cohort study.

Am J Ophthalmol 2021 May 26. Epub 2021 May 26.

Department of Ophthalmology & Visual Sciences, College of Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242-1091. Electronic address:

View Article and Full-Text PDF

Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report.

J Med Case Rep 2021 May 29;15(1):307. Epub 2021 May 29.

Ophthalmology Department of Hospital general Universitario de Alicante, Alicante, Spain.

Background: We report our findings in a patient who developed central retinal vein occlusion (CRVO) and was a chronic user of olanzapine, an antipsychotic medication.

Case Presentation: A 50-year-old Caucasian man, non-smoker, was referred to our clinic with the chief complaint of floater appearance in his left eye for the past 3 days. His past medical history indicated that he had been taking antipsychotic drugs (olanzapine) for about 3 years, with no other systemic disease or risk factors for CRVO. Read More

View Article and Full-Text PDF

Prevalence of Retinal Vein Occlusions and Estimated Cerebrospinal Fluid Pressure: The Kailuan Eye Study.

Eye Brain 2021 21;13:147-156. Epub 2021 May 21.

Beijing Institute of Ophthalmology and Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.

Purpose: To investigate the prevalence of retinal vein occlusions (RVOs) and associated factors in a Chinese population.

Patients And Methods: The cross-sectional community-based Kailuan Eye Study included individuals who participated in the Kailuan Study. RVOs were diagnosed on the fundus photographs. Read More

View Article and Full-Text PDF

Racial Differences in Anti-VEGF Intravitreal Injections Among Commercially Insured Beneficiaries.

Ophthalmic Surg Lasers Imaging Retina 2021 Apr 1;52(4):208-217. Epub 2021 Apr 1.

Background And Objective: This study assessed racial and ethnic differences in receiving anti-vascular endothelial growth factor (VEGF) intravitreal injections among commercially insured patients.

Patients And Methods: A retrospective cohort study of 104,430 patients diagnosed with wet age-related macular degeneration (AMD), diabetic retinopathy, central retinal vein occlusion (CRVO), and branch retinal vein occlusion (BRVO) in the Optum Research Database between 2011 and 2016. Main outcomes included receiving an intravitreal anti-VEGF treatment; the first type of treatment received, if any; and subsequent treatment with ranibizumab or aflibercept among patients who were first treated with bevacizumab. Read More

View Article and Full-Text PDF

The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy.

Eye (Lond) 2021 May 25. Epub 2021 May 25.

National Institute for Health Research, Moorfields Biomedical Research Centre, London, UK.

Aims: To report, using ultra-widefield angiography (UWFA) the area, distribution, and change in retinal capillary nonperfusion (RCNP) at baseline and 100 weeks in eyes with central retinal vein occlusion (CRVO) receiving anti-VEGF for macula oedema.

Methods: Prospective longitudinal multi-centre cohort study. Adults with CRVO treated with anti-VEGF therapy for macular oedema underwent UWFA at baseline and week-100. Read More

View Article and Full-Text PDF

Home vision monitoring in patients with maculopathy: Real-life study of the OdySight application.

J Fr Ophtalmol 2021 Jun 20;44(6):873-881. Epub 2021 May 20.

Aix Vision, collectif P1,5, 44, avenue Maréchal-de-Lattre-de-Tassigny, 13090 Aix-en-Provence, France.

Introduction: The goal of the present study was to analyze the implementation and clinical efficacy of OdySight, a mobile medical application for the remote monitoring of patients with maculopathy.

Materials And Methods: In all, 60 patients with edematous maculopathies receiving traditional clinical treatment (PRN or Treat & Extend) were provided with OdySight to detect changes in visual acuity from home. To determine both the feasibility and reliability of the application, its use by patients (both testing and game play), as well as the processing of alerts by the clinical team, were analyzed during the first year. Read More

View Article and Full-Text PDF

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective.

BMC Ophthalmol 2021 May 24;21(1):229. Epub 2021 May 24.

School of Pharmaceutical Science and Technology, Tianjin University, Nankai District, Room 209, 24th building, 92th Weijin Road, Tianjin, 300072, China.

Background: Clinical trials in China have demonstrated that ranibizumab can improve the clinical outcomes of branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). However, no economic evaluation of ranibizumab has been conducted among Chinese patient population.

Methods: To provide insights into the economic profile of ranibizumab among Chinese RVO population, a Markov state-transition model was used to predict the outcomes of ranibizumab comparing to laser photocoagulation and observational-only care from the societal perspective. Read More

View Article and Full-Text PDF